The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam by Oliveira, Maura S. de et al.
The minimal inhibitory concentration for sulbactam
was not associated with the outcome of infections
caused by carbapenem-resistant Acinetobacter sp.
treated with ampicillin/sulbactam
Maura S. deOliveira,I Silvia Figueiredo Costa,II Ewerton de Pedri,II Inneke van der Heijden,II Anna Sara S. LevinI,II
IHospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Department of Infection Control, Sa˜o Paulo/SP, Brazil. II Faculdade de
Medicina da Universidade de Sa˜o Paulo, Department of Infectious Diseases and LIM-54, Sa˜o Paulo/SP, Brazil.
OBJECTIVE: The objective of this study was to evaluate whether the outcomes of carbapenem-resistant
Acinetobacter infections treated with ampicillin/sulbactam were associated with the in vitro susceptibility
profiles.
METHODS: Twenty-two infections were treated with ampicillin/sulbactam. The median treatment duration was
14 days (range: 3-19 days), and the median daily dose was 9 g (range: 1.5-12 g). The median time between
Acinetobacter isolation and treatment was 4 days (range: 0-11 days).
RESULTS: The sulbactam minimal inhibitory concentration (MIC) ranged from 2.0 to 32.0 mg/L, and the MIC was
not associated with patient outcome, as 4 of 5 (80%) patients with a resistant infection (MIC$16), 5 of 10 (50%)
patients with intermediate isolates (MIC of 8) and only 1 of 7 (14%) patients with susceptible isolates (MIC #4)
survived hospitalization.
CONCLUSION: These findings highlight the need to improve the correlation between in vitro susceptibility tests
and clinical outcome.
KEYWORDS: Antimicrobial Susceptibility; Resistance; Treatment.
Oliveira MS, Costa SF, de Pedri E, van der Heijden I, Levin AS. The minimal inhibitory concentration for sulbactam was not associated with the
outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam. Clinics. 2013;68(4):569-573.
Received for publication on November 5, 2012; First review completed on December 2, 2012; Accepted for publication December 2, 2012
E-mail: mauraoliveira@yahoo.com.br
Tel.: 55 11 2661-7066
& INTRODUCTION
Infections caused by carbapenem-resistant Acinetobacter
spp. are therapeutically challenging because treatment
options are limited. The most studied of these options include
polymyxins and sulbactam. Sulbactam, a synthetic beta-
lactam, is mainly used as a beta-lactamase inhibitor, but it
exhibits in vitro activity against Acinetobacter spp. (1) and has
been used to treat infections caused by this organism. In vitro
susceptibility testing for sulbactam and Acinetobacter spp. are
problematic for multiple reasons. First, the minimal inhibitory
concentration (MIC) breakpoint for sulbactam has not been
determined. As a result, the criterion for an ampicillin/
sulbactam combination is typically used instead (2). Second,
unacceptably high proportions of errors associated with the
disk diffusion method have been published. In one study, 196
clinical isolates of Acinetobacter spp. were tested using disk
diffusion and broth microdilution, and unacceptably high
proportions of errors occurred for ampicillin/sulbactam (A/
S) (very major: 9.8%; minor: 16.1%) (3) Third, the MIC
breakpoints used to interpret results are not well studied and
may not predict clinical outcomes.
The objective of this study was to evaluate whether the
outcomes of patients with carbapenem-resistant Acinetobacter
infections treated with A/S were associated with the in vitro
susceptibility profiles.
& METHODS
This study was conducted at Hospital das Clı´nicas, a
1,988-bed, tertiary-care teaching hospital affiliated with the
University of Sa˜o Paulo. We performed a retrospective
review of all patients who visited the hospital from 2000
through 2004 for carbapenem-resistant Acinetobacter bau-
mannii (CRAB) bacteremia and were treated with at least 4
doses of A/S. Information was collected from the patients’
medical records. Infection diagnoses were based on CDC
criteria (4) and were obtained from the infection-control
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database. Patients were excluded if they had received
polymyxin simultaneously.
Isolates were phenotypically identified using an auto-
mated method (Vitek; bioMerieux; Hazelwood; MO; USA)
and confirmed using classical microbiological techniques.
The antimicrobial activities of sulbactam were evaluated
against carbapenem-resistant Acinetobacter sp. isolates.
Carbapenem resistance was defined as resistance to
imipenem by broth microdilution susceptibility testing
using the Clinical and Laboratory Standards Institute
(CLSI) criteria (MIC$16 mg/L). Imipenem powder was
obtained from Merck & Co., Inc. (EUA).
The sulbactam MIC was determined using the broth
microdilution method according to the CLSI guidelines (5).
Sulbactam powder was obtained from European
Pharmacopoeia Reference Standards CRS & BRP (EDQM
European for the Quality of Medicines and Healthcare;
Council of Europe; Catalogue code Y0000528). The culture
medium consisted of cation-adjusted Mueller-Hinton broth
(BBLTM Becton Dickinson). A standardized inoculum was
prepared using the direct colony suspension method. Each
bacterial suspension was adjusted to the 0.5 McFarland
turbidity standard (1 to 26108 CFU/mL) using a photometric
device (colorimeter VitekH1, BioMe´rieux, Etoile, France). The
adjusted inoculum suspension was diluted in broth to achieve
each an approximate final concentration of 56105 CFU/mL in
each well. The sulbactam final concentrations were 0.25, 0.5, 1,
2, 4, 8, 16, 32, 64 and 128 mg/L. Escherichia coli ATCC 25922
and Pseudomonas aeruginosa ATCC 27853 were used as quality
control (QC) strains. The MIC results were evaluated by at
least 3 observers.
We described the characteristics of the patients, infec-
tions, treatments, mortality outcomes during treatment, in-
hospital mortality and clinical failure (defined as death or
persistent signs and symptoms of infection, persistent
isolation of Acinetobacter or a change in the antibiotic
between day 3 and 7 of A/S treatment).
Bivariate analysis was performed for 2 outcomes (mor-
tality during treatment and in-hospital mortality).
Multivariate analysis using logistic regression was per-
formed for in-hospital mortality. Data were analyzed using
EpiInfo 3.5.2 (CDC, Atlanta, GA).
& RESULTS
Sixty-three CRAB infections occurred in 58 patients; of
these, 20 received no treatment, 22 received A/S, 10
received colistin, 4 received colistin + A/S, and records
were not available for 2 patients. The mean age of the
studied patients was 48 years (SD: 23.3). Of the total
patients, 64% were male, 21 (96%) used central venous
catheters, 16 (73%) used urinary catheters, and 12 (55%)
required mechanical ventilation. The median treatment
duration was 14 days (range: 3-19 days), and the median
daily dose was 9 g (range: 1.5-12 g). The median time
between Acinetobacter isolation and treatment was 4 days
(range: 0-11 days). Eight patients (36%) received simulta-
neous carbapenems, and 13 (59%) received vancomycin. A
description of the studied cases is shown in Table 1.
The sulbactam MICs ranged from 2.0 to 32.0 mg/L. Five
(23%) patients were classified as resistant, 7 (32%) were
susceptible, and 10 (45%) were intermediate. Clinical failure
occurred in 7 (33%) patients. Seven (33%) patients died
during treatment, and 12 patients (55%) died during
hospitalization. The outcomes stratified by the sulbactam
MICs are depicted in Figure 1. Bivariate analyses showed
that male sex and ICU admission were risk factors for in-
hospital mortality (Table 2).
Multivariate analysis revealed that male sex (OR 15.16; 95%
CI: 1.15-200.41) and admission to the ICU (OR: 15.20; 95% CI:
1.15-200.40) were associated with in-hospital mortality. The
MICs for sulbactam and simultaneous treatment with carba-
penems were not associated with patient outcome.
& DISCUSSION
Sulbactam, a beta-lactamase inhibitor, also exhibits
intrinsic activity against Acinetobacter spp., including carba-
penem-resistant strains, and therefore represents an alter-
native to treatment with polymyxins (6). However, the
optimal treatment for multidrug-resistant Acinetobacter
infections has not been established (7).
Our case series involved 22 patients with mainly catheter-
associated bloodstream infections. Surprisingly, patients
infected with Acinetobacter who demonstrated higher MICs
were more severely ill but had lower in-hospital mortality
rates. Correlating in vitro antimicrobial susceptibility profiles
with in vivo clinical outcomes can be difficult. First,
appropriate breakpoints should be set. Breakpoints may
originally be defined as the concentrations that distinguish
subpopulations based on the MIC distribution, although
these determinations are also used to guide therapy.
Therefore, the use of breakpoints originally created to
distinguishmicrobiological subpopulations to predict clinical
success may be problematic. The EUCAST defined the latter
breakpoint as a ‘‘clinical breakpoint’’ and the former as a
‘‘microbiological or epidemiological breakpoint’’. However,
this terminology is not universal, and several current guide-
lines do not make these distinctions (8). To our knowledge,
these differences have not been evaluated for A/S, and in our
case-series, it appeared that the breakpoints did not
adequately predict patient outcomes.
It is always difficult to define the exact cause of death in
patients with multi-resistant infections because they often
exhibit several underlying diseases, receive invasive proce-
dures and have been hospitalized for long periods (9). In our
study, only admission to the ICU and sex were indepen-
dently associated with in-hospital mortality. Admission to
the ICU reflects the severity of the patient’s condition, but we
cannot explain the influence of gender on mortality.
Clinical efficacy is also influenced by the pharmacoki-
netics/pharmacodynamics of antimicrobials, which may be
altered in critically ill patients. A recent study in an ex vivo
human model showed that doses of 0.5 and 1 g of sulbactam
infused over 30 minutes resulted in bactericidal serum levels
at 2 hours after treatment. However, net regrowth and a trend
to regrowth occurred, which suggests that a desirable length
of time above a MIC.50% would not be achieved with the
common dosage regime (1 g every 6 hours) (10).
In addition, in vitro susceptibility tests for sulbactam
against Acinetobacter spp. may not be reliable. In one study,
196 clinical isolates of Acinetobacter spp. were tested by disk
diffusion and broth microdilution, and unacceptably high
proportions of errors occurred for A/S (very major: 9.8%;
minor: 16.1%) (3). Another study evaluated the activity of
sulbactam-containing combinations by broth microdilution
against 469 Acinetobacter isolates and concluded that testing
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Table 2 - Bivariate analysis of factors associated with in-hospital mortality andmortality during treatment in patients with
carbapenem-resistant Acinetobacter spp. infections treated with ampicillin-sulbactam. Hospital das Clı´nicas, University of
Sa˜o Paulo, Brazil.
In-hospital mortality Mortality during treatment
Non-survivors
(n=12)
Survivors
(n = 10) RR (95% CI) p
Death during
treatment (n= 7)
Survivors until the end
of treatment (n=15) RR (95% CI) p
Age (years)
Mean (SD) 56.3 (21.6) 44.2 (21) 0.11 48.9 (23.7) 51.7 (21.6) 0.97
Median (range) 61 (7-84) 45 (16-81) 58 (7-67) 55 (16-84)
Male gender (%) 10 4 2.86 (0.82-9.92) 0.04 6 8 3.42 (0.49-23.6) 0.15
APACHE II score (points) 0.44 0.64
Mean (SD) 15.9 (5.3) 14.2 (4.0) 16(5.7) 14.7 (4.4)
Median (range) 15 (9-23) 14.5 (7-19) 16 (9-22) 15 (7-23)
Admission to ICU (%) 10 4 2.86 (0.82-9.92) 0.04 5 9 1.43(0.35- 5.74) 0.61
Acinetobacter infection site (n) 0.50
Bloodstream infection 10 8 7 11 0.32
Pneumonia 2 1 0 3
Surgical site infection 0 1 0 1
Time between isolation and
beginning of treatment
(days)
0.10 0.06
Mean (SD) 3.5 (1.5) 5.1 (3.2) 3.0 (1.0) 4.8 (2.9)
Median (range) 3 (1-7) 5 (0-11) 3 (1-4) 5 (0-11)
Daily Dose (grams) 6.8 (3.9) 9.6 (3.7) 0.21
Mean (SD) 6.7 (3.9) 9.0 (3.7) 0.21
Median (range) 6 (1.5-12) 10.5 (3-12) 6 (1.5-12) 10.5 (3-12)
Simultaneous use of
carbapenem(n)
6 2 1.75(0.85-3.61) 0.15 3 5 1.31(0.39-4.44) 0.66
MIC (mg/L) 0.19 0.24
# 4 5 2 1 6
8 6 4 5 5
$16 1 4 1 4
SD: standard deviation, MIC: minimum inhibitory concentration.
Figure 1 - Clinical outcome, mortality during treatment, in-hospital mortality and median APACHE II score of patients with infections
caused by Acinetobacter spp. stratified by the minimum inhibitory concentration (MIC) ampicillin/sulbactam. Hospital das Clı´nicas,
University of Sa˜o Paulo, Brazil.
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with the inhibitor at a fixed ratio resulted in more reliable
results compared to a fixed concentration (11).
Our studywas limited by the small number of patients and
its retrospective design. To balance these limitations, we used
strict diagnostic criteria for infections, included only blood
isolates and used mortality as the main endpoint.
Unfortunately, we did not have data concerning catheter
removal.
In summary, in this cases series, the MIC was not
associated with patient outcome, as 4 of 5 (80%) patients
with a MIC$16 mg/mL (considered resistant), 5 of 10 (50%)
patients with a MIC of 8 mg/mL (considered intermediate),
and 1 of 7 (29%) patients with a MIC#4 mg/mL (considered
susceptible) survived hospitalization. Although we sought to
determine alternative sulbactam breakpoints for Acinetobacter
infections, this was not possible, which highlights the need
for additional studies to improve the correlation between in
vitro susceptibility tests and clinical outcome.
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